

# Share Purchase Plan - Extension of Closing Date

New Closing Date on 10 May 2024

**BRISBANE, AUSTRALIA, May 2 2024**: AnteoTech Ltd (ASX: ADO) (AnteoTech or the Company) a revenue stage company, providing solutions for the clean energy and life sciences markets using proprietary applied materials technology, advises that the closing date of its Share Purchase Plan (SPP) announced on 8<sup>th</sup> April 2024 is being extended until 5pm Friday 10<sup>th</sup> May 2024.

The SPP provides each Eligible Shareholder with the opportunity to apply for up to \$50,000 worth of new shares at the same issue price as the placement announced on 8 April 2024, being \$0.025 (2.5 cents), per New Share.

The Company intends to raise an additional \$1.0 million with the ability to accept oversubscriptions. The SPP is offered under a Prospectus, enabling shareholders to apply up to a \$50,000 limit per holding, rather than a maximum of \$30,000 as is usually the case, and whether or not they participated in the Company's prior SPP in August 2023.

## **Options**

Subject to Shareholder approval, Eligible Shareholders (being those Shareholders who participate in either the SPP or the Placement) are also entitled to one free attaching option (New Option) for every two New Shares subscribed for under the SPP or the Placement, respectively. The New Options will be exercisable at \$0.035 (3.5 cents) and will expire two (2) years after the date of issue. The Company will seek quotation of the New Options on the ASX.

## **Bonus Options**

In addition to the New Options, Eligible Option holders are to be issued with one free attaching bonus option (Bonus Option) for each New Option exercised on or before 12 months from the date of issue of the New Options (Bonus Option Cut-off Date). The Bonus Options will be exercisable at \$0.05 (5 cents) per Bonus Option and will expire on 30 April 2027. The Company will not apply for the Bonus Options to be quoted on the ASX.

The full terms and conditions of the SPP are included in the SPP Prospectus announced to the ASX on 19 April 2024 which is available for download from the offer website <a href="https://events.miragle.com/ado-spp">https://events.miragle.com/ado-spp</a>

The revised timetable for the SPP is as follows:

Lodgement of Prospectus with ASIC	19 April 2024
Offers open	19 April 2024
Issue Notice of Meeting	26 April 2024
Offers close	10 May 2024
Announcement of results of Share Purchase Plan	14 May 2024
Issue of New Shares under the Share Purchase Plan	15 May 2024
Quotation of New Shares issued under the Share Purchase Plan on ASX	16 May 2024
Dispatch of holding statements for New Shares issued under the Share Purchase Plan	17 May 2024
Extraordinary General Meeting to approve issue of New Options and director participation in the Placement	28 May 2024
Quotation of New Options on ASX	31 May 2024
Issue of New Options under Placement and Share Purchase Plan	31 May 2024
Dispatch of holding statements for New Options	3 June 2024





The Company reserves the right to vary these times and dates (other than in respect of events that have already occurred). All times are Australian Eastern Standard time. The Company also reserves the right to accept late applications at its discretion.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

Media and investor enquiries: +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

## About AnteoTech Ltd (ASX:ADO)

AnteoTech is a revenue-stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo X<sup>™</sup>, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry. The portfolio includes a proprietary high silicon anode, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets; from global diagnostics companies to technology developers. The unique characteristics of AnteoBind™ provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

## **AnteoTech - Social Media Policy**

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter (@AnteoTech\_), LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

## **Forward Looking Statements**

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (Estimates and Projections). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to AnteoTech' business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

